Rybelsus®

Semaglutide

Rybelsus tabletter (semaglutide) er et reseptbelagt legemiddel som brukes hos voksne med type 2 diabetes mellitus for å redusere blodsukkernivået. Rybelsus kan foreskrives når andre diabetesmedisiner har blitt prøvd uten suksess og bør brukes sammen med kosthold og trening. Rybelsus tabletter arbeider for å senke blodsukkernivået (glukose) ved å øke hvor mye insulin som frigjøres og redusere glucagon sekresjon. Denne medisinen kan også bremse gastrisk tømming etter å ha spist.
more
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 164.78
kr 14830.42kr 164.78
kr 1976.36
60 tablet
Gratis AirMail sending Hot
kr 175.77
kr 10545.91kr 175.77
kr 658.60
30 tablet
Gratis AirMail sending Hot
kr 186.74
kr 5602.26kr 186.74
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 197.74
kr 17796.61kr 197.74
kr 987.63
60 tablet
Gratis AirMail sending Hot
kr 203.23
kr 12193.80kr 203.23
kr 329.03
30 tablet
Gratis AirMail sending Hot
kr 208.71
kr 6261.41kr 208.71
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 236.19
kr 21257.17kr 236.19
kr 987.63
60 tablet
Gratis AirMail sending Hot
kr 241.68
kr 14500.84kr 241.68
kr 329.03
30 tablet
Gratis AirMail sending Hot
kr 247.16
kr 7414.93kr 247.16
Rybelsus

Merke(r)

Produsenter

  • Novo Nordisc India Pvt. Ltd

Sykdommer

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.